Perspective Therapeutics develops radiopharmaceutical candidates for cancer using proprietary Lead-212 (212Pb) technology and specialized targeting moieties. Its updates center on a theranostic approach that pairs targeted alpha therapy with complementary imaging diagnostics.
Recurring CATX news covers clinical and conference updates for VMT-α-NET in SSTR2-expressing neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors, along with business results, financing activity, manufacturing infrastructure, 212Pb generator-enabled finishing facilities, and corporate presentations.
Perspective Therapeutics (CATX) reported a third-quarter 2026 net loss of $32.442 million while advancing its radiopharmaceutical clinical programs. Loss per share was $0.27 versus $0.35 a year earlier, while net loss widened from $25.969 million. Cash, cash equivalents and short-term investments totaled approximately $202 million at September 30, 2026; the company expects this to fund current planned milestones and operational investments into 2028.
Bamzireotide completed enrollment in its fourth dose-finding cohort, with 20 patients; Perspective targets an FDA end-of-Phase 2 meeting in 1Q 2027. VMT01 enrollment continues to corroborate interim melanoma findings. PSV359 received FDA Fast Track designation for specified solitary fibrous tumors, and a Merck agreement supports potential combination testing with Keytruda. The company expects construction at its Chicago metro manufacturing site to finish in early 2027.
Perspective Therapeutics (CATX) reported interim Phase 1/2a results for lapemelanotide zapixetar monotherapy in heavily pretreated advanced melanoma, showing 75% disease control at the focus dose.
At 3.0 mCi, two of eight enrolled patients had partial tumor responses; one remained in partial response and on study approximately 40 weeks after first treatment. Disease control included two patients with long-lasting disease stabilization. The eighth patient was not yet eligible for a first tumor assessment.
Across 20 patients in three dose cohorts as of September 18, 2026, no dose-limiting toxicities, treatment-related serious adverse events or adverse-event-related treatment discontinuations were reported. Grade 3 or higher adverse events occurred in five patients (25%); none were considered treatment-related. The company plans continued evaluation and dose optimization to inform future development.
Perspective Therapeutics (CATX) reported additional Phase 1/2a data for bamzireotide navoxetan in patients with advanced neuroendocrine tumors expressing SSTR2 receptors. Among 57 patients with gastroenteropancreatic tumors whose target lesions all expressed SSTR2, the response rate was 39%, disease control was 95%, and survival without progression was 75% at 18 months. This subgroup analysis was retrospective, and response rates included responses awaiting confirmation.
Across 68 treated patients, no dose-limiting toxicities or treatment-related discontinuations were reported. Grade 3 treatment-emergent adverse events occurred in 29%; two patients experienced Grade 3 acute kidney injuries during follow-up. Perspective targets an end-of-Phase 2 meeting in the first quarter of 2027; Phase 3 initiation in 2027 depends on FDA feedback and completion of clinical, regulatory and operational activities.
Perspective Therapeutics (CATX) reported interim Phase 1/2a results for VMT-α-NET in advanced neuroendocrine tumors expressing the SSTR2 protein targeted by treatment. Among patients without prior radiopharmaceutical therapy, objective response rates, including unconfirmed responses, were 33% in Cohort 2 and 50% in Cohort 3. These cohorts included 46 and 20 patients receiving 5.0 mCi and 6.0 mCi, respectively; Cohort 3 includes updates through September 10, 2026. Disease control rates were 89% and 95%, respectively. Across all 68 patients, survival without disease progression was 72% at 18 months.
No dose-limiting toxicities or adverse event-related discontinuations occurred. Grade 3 treatment-emergent adverse events affected 29%; two patients had Grade 3 renal events. Perspective targets Phase 3 site preparations around year-end 2026 and expects initiation in 2027, following an FDA End-of-Phase 2 meeting.
Perspective Therapeutics (CATX) received FDA Fast Track designation for PSV359 development in adults with advanced FAP-positive solitary fibrous tumors. The designation covers locally advanced tumors that cannot be surgically removed and/or metastatic disease. PSV359 is an investigational therapy that targets fibroblast activation protein (FAP) and delivers radiation using lead-212.
The treatment is being evaluated in an ongoing Phase 1/2a study in patients with advanced FAP-positive solid tumors. The dose-finding phase assesses safety and tolerability to inform selection of a recommended Phase 2 dose. Fast Track may enable more frequent FDA interactions. Rolling review, Accelerated Approval and Priority Review remain separate programs with their own qualifying requirements.
Perspective Therapeutics (CATX) announced acceptance of [²¹²Pb]VMT-α-NET data for presentation at the NANETS symposium, taking place November 5–7, 2026, in Las Vegas.
Thorvardur Halfdanarson of Mayo Clinic Rochester will give an oral presentation on cohort-level safety and efficacy results in advanced neuroendocrine tumors expressing somatostatin receptor subtype 2, a protein the treatment targets. The abstract covers Cohorts 1–3 and is scheduled for November 5 during the Featured Abstracts I session, from 4:10 to 5:25 p.m. PST.
Perspective Therapeutics (CATX) announced acceptance of its [212Pb]VMT01 melanoma program data for presentation at SITC’s annual meeting in November 2026. The phase I/IIa trial poster covers treatment alone and with nivolumab and is scheduled for November 6, 2026, in Phoenix.
Previously presented ASCO interim results, with a March 25, 2026 data cutoff, included two responders among seven patients in the 3.0 mCi monotherapy cohort. Six patients (86%) had stable disease or a partial response. Across 27 treated patients, eight (30%) experienced Grade 3 treatment-emergent adverse events. There were no dose-limiting toxicities, adverse-event-related discontinuations, or Grade 4 or Grade 5 treatment-emergent adverse events.
Perspective Therapeutics (CATX) announced a clinical trial collaboration and supply agreement with Merck (MRK)/b) on September 14, 2026 to evaluate Perspective’s targeted alpha therapy in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in FAP-α–positive solid tumors.
The combination will be tested via an amendment to Perspective’s ongoing Phase 1/2a, multi-center, open-label, dose-finding and dose-expansion study (NCT06710756) in patients with certain non-small cell lung and colorectal cancers expressing FAP-α. The study has completed enrollment in the first three monotherapy dose cohorts. Perspective sponsors the trial, while Merck supplies pembrolizumab at no cost. PSV359 is designed to deliver the alpha-emitting isotope 212Pb to FAP-α–expressing tumors, with related imaging agents (203Pb/68Ga, PSV377) used to select patients and assess FAP-α expression.
Perspective Therapeutics (CATX) reports that updated data from its [212Pb]VMT-α-NET program have been accepted for presentation at the 38th EORTC-NCI-AACR Symposium 2026 in Barcelona.
The poster, led by Vikas Prasad of Washington University School of Medicine, will show cohort-level safety and efficacy results for [212Pb]VMT-α-NET in advanced SSTR2-positive neuroendocrine tumors (NETs), covering Cohorts 1–3, as Abstract 334 in the “New drugs” poster session on November 20, 2026.
[212Pb]VMT-α-NET is being evaluated in a multi-center, open-label, dose-escalation and dose-expansion trial (NCT05636618) in unresectable or metastatic SSTR2-positive tumors without prior radiopharmaceutical therapy, with additional data submissions planned for 2026 and 2027.
Perspective Therapeutics (NYSE American: CATX) reported 2Q 2026 results and pipeline progress, led by bamzireotide navoxetan (VMT-α-NET) in SSTR2-positive neuroendocrine tumors, which is being advanced toward a Phase 3 study targeting site activation around year-end 2026, subject to regulatory feedback.
VMT-α-NET has treated 76 NETs patients plus one meningioma patient, with ASCO 2026 interim data showing continued deepening of response and an ESMO 2026 oral update planned. The company also reported ongoing VMT01 melanoma and PSV359 solid tumor studies, pre-IND work on PSV594, manufacturing build-outs in Chicago and Los Angeles through 2027, cash and investments of about $237 million, and a 2Q 2026 net loss of $26.8 million, or $0.22 per share.